Oncocross Co., Ltd. announced that it has received KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors
October 26, 2023
Share
On October 27, 2023, Oncocross Co., Ltd. closed the transaction.
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
Oncocross Co., Ltd. announced that it has received KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors
DONGWHA PHARM.CO.,LTD 
